Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Oliver Sartor MD
Oliver Sartor MD Advisory Board
Alexander van Akkooi MD, PhD, FRACS
Alexander C. J. van Akkooi MD, PhD, FRACS Associate Editor
Rafael Fonseca MD
Rafael Fonseca MD Editor-in-Chief
See All Experts
Published in Oncology

Journal Scan / Research · March 29, 2018

XELIRI Noninferior to FOLFIRI as Second-Line Therapy for Metastatic Colorectal Cancer

The Lancet Oncology

 

 Save  Recommend
 Share

Additional Info

The Lancet Oncology
Modified XELIRI (Capecitabine Plus Irinotecan) Versus FOLFIRI (Leucovorin, Fluorouracil, and Irinotecan), Both Either With or Without Bevacizumab, as Second-Line Therapy for Metastatic Colorectal Cancer (AXEPT): A Multicentre, Open-Label, Randomised, Non-Inferiority, Phase 3 Trial
Lancet Oncol 2018 Mar 16;[EPub Ahead of Print], RH Xu, K Muro, S Morita, S Iwasa, SW Han, W Wang, M Kotaka, M Nakamura, JB Ahn, YH Deng, T Kato, SH Cho, Y Ba, H Matsuoka, KW Lee, T Zhang, Y Yamada, J Sakamoto, YS Park, TW Kim

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Recently Updated